Check@Home: General population screening for early detection of atrial fibrillation and chronic kidney disease
- Conditions
- Cardiovasular diseasekidney disease100075211001842410038430
- Registration Number
- NL-OMON56780
- Lead Sponsor
- Amsterdam UMC
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 160000
Inclusion Criteria
age 50-75 years
living in one of the four participating regions in the Netherlands
Exclusion Criteria
age <50 or >75 years living outside the participating regions being
institutionalized having participated in the previously conducted THOMAS Study
(NL65228.042.18, METc 2018/687)
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Overall effectiveness of population based screening on atrial fibrillation and<br /><br>chronic kidney disease (defined by elevated albuminuria) in subjects aged 50-75<br /><br>years, based on:<br /><br>- Participation rate of different screening strategies and phases<br /><br>- Yield of the screening (number of subjects with (newly) diagnosed disease and<br /><br>risk factors)<br /><br>- Effectiveness of the different screening and treatment strategies on the main<br /><br>(combined) endpoint (as defined in protocol section 10.1), compared to standard<br /><br>care </p><br>
- Secondary Outcome Measures
Name Time Method <p>Overall effectiveness of population based screening on heart failure, coronary<br /><br>artery disease, and diabetes type 2 in subjects aged 50-75 years, based on:<br /><br>- Effectiveness of different screening and treatment strategies on other<br /><br>cardiovascular events, compared to standard care<br /><br>- Cost-effectiveness of different screening strategies, compared to standard<br /><br>care<br /><br>- Safety of the atrial fibrillation screening and treatment program, compared<br /><br>to standard care</p><br>